secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001564590-22-019070
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma reports Q1 2022 net loss of $18.4M; cash at $294.8M; ASCO presentation on PC14586
--------------------------------------------------------------------------------

- Net loss of $18.4M for Q1 2022 vs $11.6M in Q1 2021; R&D spend increased to $11.8M.
- Cash, equivalents and marketable securities totaled $294.8M as of March 31, 2022, down from $314.1M at year-end 2021.
- Initial Phase 1/2 data for PC14586 (p53 Y220C reactivator) selected for oral presentation at ASCO 2022 on June 7.
- Continued advancement of WIP1 inhibitor and p53 mutant pipeline programs.
- Net cash used in operations was $18.0M in Q1 2022 vs $12.9M in Q1 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000156459022019070/0001564590-22-019070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000156459022019070/pmvp-8k_20220510.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-019070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer